1. Home
  2. RDHL

as of 05-11-2026 10:05am EST

$0.97
$0.04
-3.95%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Founded: 2009 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 5.4M IPO Year: 2012
Target Price: N/A AVG Volume (30 days): 56.4K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.71 - $3.31 Next Earning Date: 04-27-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 381.91% Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered RDHL Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 18 hours ago

AI Recommendation

hold
Model Accuracy: 75.74%
75.74%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Redhill Biopharma Ltd. (RDHL)

Raday Gilead

Chief Operating Officer

Sell
RDHL Apr 6, 2026

Avg Cost/Share

$0.00

Shares

15,740,000

Total Value

$1,574.00

Owned After

261,060,000

SEC Form 4

Share on Social Networks: